机构投资者在赚取了丰厚的收入后增加了Edwards Lifesciences的股份,并增加了指导,尽管内幕人士出售。 Institutional investors increased holdings in Edwards Lifesciences after strong earnings and raised guidance, despite insider selling.

机构投资者Holcene Advisors and Hudson Bay Capital在问题2期间提升了他们在Edwards Lifesciences的股权,其理由是Q3收入强劲,有6.7 EPS和15.5亿美元的收入,即14.7%的年增长率。 Institutional investors Holocene Advisors and Hudson Bay Capital boosted their stakes in Edwards Lifesciences during Q2, citing strong Q3 earnings with $0.67 EPS and $1.55 billion in revenue, a 14.7% year-over-year rise. 该公司提出了2025年全年和Q4指导意见,而分析师则维持了“购买模式”共识,平均价格目标是93.30美元。 The company raised 2025 full-year and Q4 guidance, while analysts maintained a “Moderate Buy” consensus with an average price target of $93.30. 尽管出现了积极势头,但内幕出售活动仍时有发生,主管在90天内出售380万美元的股票。 Despite positive momentum, insider selling occurred, with executives selling $3.8 million in shares over 90 days. 股票以83.06美元关闭,市场上限为482亿美元。 The stock closed at $83.06 with a market cap of $48.2 billion.